Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

BACKGROUND: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I da...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pignata, Sandro, Scambia, Giovanni, Savarese, Antonella, Breda, Enrico, Scollo, Paolo, De Vivo, Rocco, Rossi, Emanuela, Gebbia, Vittorio, Natale, Donato, Del Gaizo, Filomena, Naglieri, Emanuele, Ferro, Antonella, Musso, Pietro, D'Arco, Alfonso Maria, Sorio, Roberto, Pisano, Carmela, Di Maio, Massimo, Signoriello, Giuseppe, Annunziata, Annalisa, Perrone, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2006
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1553473/
https://ncbi.nlm.nih.gov/pubmed/16882344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-202
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados